Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2592942 | 0.87 | ALOX5AP (0.31) | — | |
| SCHEMBL2588451 | 0.86 | ALOX5AP (0.30) | — | |
| SCHEMBL2591532 | 0.77 | MEN1 (0.36) | — | |
| SCHEMBL2591433 | 0.76 | ALOX5AP (0.34) | — | |
| SCHEMBL7713772 | 0.75 | KDM4E (0.40) | DHFRDCPS | |
| SCHEMBL2584271 | 0.75 | ALDH1A1 (0.41) | — | |
| SCHEMBL2589057 | 0.75 | ALDH1A1 (0.33) | — | |
| SCHEMBL2590931 | 0.74 | ALOX5AP (0.33) | — | |
| SCHEMBL7706052 | 0.74 | PRF1 (0.39) | — | |
| SCHEMBL2588771 | 0.73 | GSK3B (0.37) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563770-B1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-03-23 | — | — | EP | disclosed |
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| EP-2563770-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011134468-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE4A | CNR2 2470/4885CNR1 2293/4885DHFR 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.